Introduction {#Sec1}
============

With age, older individuals are at high risk of thromboembolic events. Cancer is an established cause of venous thrombosis^[@CR1]^; once a thrombus forms, venous thromboembolism (VTE) and even pulmonary embolism (PE) can result, leading to serious adverse events such as heart failure, respiratory failure, and sudden death. The prevalence of malignancy in patients with PE ranges between 4% and 20%, and almost 50% of patients with tumors have thromboses on autopsy^[@CR2],[@CR3]^. The overall risk of PE is increased twenty-fold in patients with tumors compared with the general population^[@CR4]^. In a retrospective study in 435 patients with cancer, the incidence of PE was 3.3% and the mortality rate was as high as 30%^[@CR5]^. Thrombotic events are the second leading cause of death in patients with tumors^[@CR6]^. In our hospital, 1.51% (280/18531) of patients with cancer present with (VTE), most occur within the first 6 months after cancer diagnosis and nearly half of deaths occur within the first 3 months of VTE diagnosis^[@CR7]^. Lung cancer is the sixth most common malignancy coexisting in patients with PE^[@CR8],[@CR9]^. Therefore, early diagnosis and timely treatment of thrombosis is warranted in this patient population.

However, clinical manifestations of older patients with lung cancer and PE are atypical. The National Central Cancer Registry of China (NCCR) recently reported that lung cancer was the most common cancer and the leading cause of tumor mortality in men aged 60 years and above^[@CR10]^. Most new cancer cases and tumor mortality in men occur in the age range of 60--74 years^[@CR11]^. The typical presentation forms in older patients with lung cancer complicated with PE include dyspnea, chest pain, and/or hemoptysis. In our previous study, we found that PE in patients with cancer frequently causes dyspnea (51.5%)^[@CR7]^. Compared with the younger patients, the main symptoms presented in elderly patients are dyspnea (73.4% vs 63,7%), chest pain (26.6% vs 39.5%) and cough/hemoptysis (31.3% vs 18.9%)^[@CR12]^. Therefore, missed diagnosis and misdiagnosis for PE remain relatively common in older patients. Older patients have more comorbidities, a weak organ compensatory capacity, and poor prognosis. In-hospital (13% vs 2%) and long-term (36% vs 12%) mortality rates are significantly higher in elderly patients compared with the younger population with PE^[@CR13]^. Furthermore, lung cancer complicated with PE may significantly increase treatment difficulties and health-care expenditure, reduce quality of life, and shorten survival time^[@CR14]^. Recently, Lange *et al*. studied 991 older patients (≥65 years) with acute VTE in a Swiss prospective cohort study, and found that multimorbid older patients with VTE have not only a lower anticoagulation quality but only more complications^[@CR15]^, and only 12% of patients with a malignancy complicated with VTE survive beyond 1 year^[@CR16]^. In our hospital, the median survival time of patients with cancer and complicated with isolated PE was 16.0 ± 10.5 months^[@CR7]^. However, owing to limited data, few studies have evaluated the clinical characteristics and prognosis in older patients with comorbidities of PE and cancer. Therefore, we aimed to evaluate the clinical characteristics, prognosis, and risk factors in older patients with lung cancer complicated with PE.

Methods {#Sec2}
=======

Ethical approval {#Sec3}
----------------

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Beijing Hospital. Written informed consent was obtained from all patients.

Study design and population {#Sec4}
---------------------------

This was a single-center, prospective cohort study. Older patients aged 65 and more years old with lung cancer and admitted in Beijing Hospital were enrolled. Patients who had lung cancer with PE were regarded as the PE group and patients without PE were regarded as the control group using propensity score matching.

Inclusion criteria {#Sec5}
------------------

\(1\) Patients aged 65 and more years old; (2) lung cancer was diagnosed by histological or cytological examination; (3) PE and risk classification was diagnosed in line with the PE diagnosis and treatment guidelines of the Chinese Thoracic Society.

Exclusion criteria {#Sec6}
------------------

\(1\) Primary tumor other than lung cancer; (2) diagnosis of PE prior to admission; (3) presence of severe liver failure, renal failure, or other organ dysfunction; (4) incomplete data.

Procedures {#Sec7}
----------

Patients' medical information were collected from the hospital information system or medical record system. A self-designed data collection form was used to record demographic data, medical history, laboratory examination, and CT pulmonary angiography features. Tumor-related data included tumor histology, clinical stage, and treatment modality. PE-related conditions included time between PE diagnosis and lung cancer diagnosis, symptoms, risk stratification, and treatments^[@CR7]^. All clinical characteristics of DVT were collected within 1 month of diagnosis.

Follow-up {#Sec8}
---------

All patients were followed up, mainly by telephone communication and outpatient visit. Follow-up data were recorded until December 2017 or death. Date of death was confirmed from registration data of the Department of Civil Affairs of China. Survival time was defined as the time from the diagnosis until death or truncation, which included patients who were lost to follow-up or still alive at the time of study termination^[@CR7]^. The primary endpoint was the overall survival rate. The secondary endpoint was the tumor-related mortality rate and PE-related mortality rate.

Statistical analyses {#Sec9}
--------------------

One-to-one matching was undertaken to overcome potential selection bias by the propensity score matching (PSM) method between the two groups. Using the multiple logistic regression analysis, a propensity score was estimated for all patients. Variables used in the model included age, sex, BMI, smoking, medical history, D-dimer, WBC, hemoglobin, platelet, PaO~2~, hemodynamic parameters, clinical TNM stage, histology and treatment. We performed caliper matching on the propensity score (nearest available matching). Pairs on the propensity score logit were matched within a range of 0.2 SD. Matching was performed by the minimal adjacent method of 1:1 pairing^[@CR17]^.

All patients were included in the analysis according to the intention-to-treat principle. Data were expressed as the mean and standard deviation for normally distributed continuous variables, and as absolute number and percentage for categorical variables. Statistical differences were analyzed using the t-test for continuous data and the χ2 test for categorical data. Kaplan--Meier survival analysis was used to evaluate the median survival time, and the log-rank test was used to determine the statistical difference between groups. After univariate analysis, all variables with *P* values less than 0.15 were considered in subsequent multivariate analyses. The odds ratio (OR value) and corresponding 95% confidence interval (CI) was calculated using stepwise multivariate logistic regression analysis to evaluate the independent risk factors for PE. A *P* value \< 0.05 was considered statistically significant. All statistical tests were two-sided. Data processing was performed using TATA software (version 12.0; StataCorp, College Station, TX, USA).

Results {#Sec10}
=======

Baseline characteristics {#Sec11}
------------------------

From January 2006 to December 2016, 7,735 patients with lung cancer were admitted to our hospital. Patients who did not meet the inclusion criteria and those with incomplete data (n = 4,229) were excluded from the analysis. There were 86 older patients with lung cancer and PE and 3,420 older patients without PE. After propensity score matching, 53 patients were categorized as the PE group and 53 patients as the control group (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Study flow diagram.

Among the 106 older patients with lung cancer, 57 were male, and the average age was (77.3 ± 10.9) years (65--90 years). Baseline characteristics such as age, sex, body mass index, smoking and risk factors, platelets and hemoglobin, clinical stage, risk stratification, and treatment were similar between the PE group and the control group (*P* \> 0.05).

Among patients with cancer and PE, adenocarcinoma was the most common histology (52.8%, n = 28), and most lung cancer patients were in stages III and IV (59.4%, n = 43). All 53 patients with PE were stratified to low risk (52.8%, n = 28), intermediate-low risk (24.5%, n = 13), intermediate-high risk (15.1%, n = 8), or high-risk (7.5%, n = 4) subgroups. In addition, most patients with PE (75.5%, n = 40) presented with dyspnea, 5 cases (9.4%) presented with chest pain, 2 cases (3.8%) presented with syncope, and 6 cases (11.3%) were asymptomatic. In the PE group, 31 patients had DVT, mostly in the lower extremities (n = 24). For the majority of patients with PE (86.8%, n = 46), PE appeared within 3 months after the diagnosis of cancer. Thirty-seven (69.8%) patients received low-molecular-weight heparin and/or warfarin anticoagulant therapy, 6 patients received intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis, and 9 patients did not receive anticoagulant or thrombolytic therapy because of contraindications (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of older patients with or without PE.DataOverall cohortPropensity score matched cohortPE group (n = 86)Control group (n = 3,420)*t/χ*^2^ value*P* valuePE group (n = 53)Control group (n = 53)*t/χ*^2^ value*P* value**Basic characteristics**Age(years)79.3 ± 12.775.2 ± 9.14.080\<0.00177.4 ± 10.877.2 ± 6.40.6470.519Male58(67.4%)2094(61.2%)1.3970.23729(54.7%)28(52.8%)0.0380.846BMI (kg/m^2^)22.7 ± 4.923.5 ± 4.21.7370.08322.1 ± 3.522.5 ± 2.7−0.6590.512Smoking52(60.4%)1941(56.8%)0.4740.49137(69.8%)33(62.3%)**Medical history**Hypertension31(36.0%)1345(39.3%)0.3830.53617(32.1%)19(35.8%)0.1680.682Diabetes35(40.7%)989(28.9%)5.6590.01715(28.3%)17(32.1%)0.1790.672COPD42(48.8%)1294(37.8%)4.1920.04133(62.3%)31(58.5%)0.1580.691Atrial fibrillation22(25.6)603(17.6)3.6190.05718(34.0%)10(18.9%)3.1060.078Varicose veins26(30.2%)665(19.4%)5.5410.01919(35.8%)13(24.5%)1.3890.239Deep vein catheterization36(41.8%)1073(31.4%)4.0720.04418(34.0%)14(26.4%)0.7180.397DVT44(51.2%)295(8.6%)99.394\<0.00131(58.5%)29(54.7%)0.1540.695**Lab. test**D-Dimer (ug/L)601.3 ± 282.2399.5 ± 375.44.949\<0.001532.3 ± 162.4489.9 ± 185.71.2510.214WBC count (×10^9^/L)8.92 ± 5.648.21 ± 5.971.0880.2778.6 ± 3.78.5 ± 4.10.1320.895Hemoglobin (g/L)110.6 ± 49.3131.2 ± 75.72.5100.012111.6 ± 26.8127.7 ± 32.52.7820.401Platelet count (×10^9^/L)182.3 ± 137.4237.4 ± 199.82.5440.011226.6 ± 86.2234.5 ± 99.10.4380.662PaO~2~ (mmHg)68.2 ± 33.876.7 ± 32.72.3790.01772.2 ± 21.379.7 ± 12.41.2330.220**Hemodynamic parameters**SBP (mmHg)107.8 ± 44.5125.4 ± 42.73.7710.0002109.7 ± 12.3113.6 ± 15.31.4460.151DBP (mmHg)62.4 ± 26.370.6 ± 17.54.227\<0.00168.5 ± 10.571.4 ± 8.51.5630.121Heart rate113.7 ± 47.593.2 ± 43.74.287\<0.001101.6 ± 13.398.2 ± 9.61.5090.134Clinical TNM stage12.0130.0021.8510.396I-II11(12.8%)427(3.7%)16(30.2%)10(18.9%)III41(47.7%)1870(54.7%)23(43.4%)27(50.9%)IV34(39.5%)1123(41.6%)14(26.4%)16(30.2%)Histology6.3240.0421.3250.516  Adenocarcinoma47(54.6%)1974(58.0%)28(52.8%)23(43.4%)  Squamous cell carcinoma22(25.6%)1081(31.6%)17(32.1%)18(34.0%)  Large cell carcinoma17(19.8%)365(10.4%)8(15.1%)12(22.6)**Treatment (%)**Surgery33(38.3%)973(26.7%)3.8200.05120(37.7%)19(35.9%)0.0410.840Chemotherapy83(96.5%)3176(92.9%)2.0570.15151(96.2%)50(94.3%)0.2110.646Targeted therapy24(27.9%)745(21.7%)1.7350.18813(24.5%)15(28.3%)0.1940.659Radiation35(37.2%)1026(30.0%)1.9930.15816(30.2%)18(34.0%)0.1730.677Anti-coagulation61(70.9%)155(4.5)256.699\<0.00137(69.8%)28(52.8%)3.7670.052Thrombolysis12(13.9%)29(0.8)42.381\<0.0017(13.2%)2(3.8%)3.2000.074PE, pulmonary embolism; BMI, body mass index; COPD, chronic obstructive pulmonary disease; WBC, white blood cells; PaO2, partial pressure of oxygen; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Prognosis {#Sec12}
---------

The median follow-up time was 23.7 months (12.0--62.0 months) and 7 patients (6.6%) were lost to follow-up, including 5 in the PE group and 2 in the control group. During the follow-up period, 92 patients (86.8%) died, including 8 cases (8.7%) of PE-related death, 73 cases (79.3%) of tumor-related death, and 11 cases (11.9%) of unknown cause. There were significant differences in all-cause mortality and PE-related mortality between the PE and the control groups, but the rate of tumor-related mortality was comparable between the two groups. Among the 92 patients who died, the mortality rates at 3, 6, 12, and \>12 months after tumor diagnosis were 46(43.4%), 18 (16.9%), 13 (12.2%), and 15 (14.2%), respectively. Kaplan--Meier survival analysis showed that the median overall survival time was significantly shorter in the PE group compared with the control group (4.3 *vs*. 9.2 months, *P* = 0.0015). However, the median tumor-related survival time was similar between the two groups (7.1 months *vs*. 9.7 months, *P* = 0.165) (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Figure 2Kaplan--Meier survival analysis of median overall survival time.Figure 3Kaplan--Meier survival analysis of tumor-related survival time.

Risk factor related to PE of all patients {#Sec13}
-----------------------------------------

Multivariate stepwise logistic regression analysis was used to identify independent risk factors for PE. Age ≥ 77 years (*OR* = 2.58, 95%*CI*: 1.66--4.01), clinical stage III--IV (*OR* = 2.21, 95%*CI*: 1.03--4.74), adenocarcinoma (*OR* = 3.24, 95%*CI*: 1.75--6.00), high D-dimer level (≥600 mg/L) (*OR* = 2.73, 95%*CI*: 1.25--5.96), and low PaO~2~ (\<75 mmHg) (*OR* = 2.85, 95%*CI*: 1.74--4.67) were identified as independent risk factors for PE (Table [2](#Tab2){ref-type="table"}).Table 2Risk factors for PE by multivariate logistic analysis.Risk factorβSEWald χ2*OR*95%CI*P* valueAge ≥77 years0.9480.22517.7522.581.66--4.01\<0.001Stage III-IV0.7930.3904.1342.211.03--4.740.042Adenocarcinoma1.1760.31414.0273.241.75--6.000.002D-Dimer ≥600ug/L1.0040.3998.7712.731.25--5.960.011PaO~2~ \< 75 mmHg1.0470.25217.2622.851.74--4.67\<0.001PE, pulmonary embolism; PaO~2~, partial pressure of oxygen.

Discussion {#Sec14}
==========

Older patients with lung cancer are susceptible to multiple risk factors for PE, including (1) patient-related factors such as advanced age, immobilization, hyperglycemia, hyperlipidemia, and smoking^[@CR18]^; (2) malignant cell-related factors^[@CR19]^, including the production of procoagulant, fibrinolytic, and proaggregating conditions; release of proinflammatory and proangiogenic cytokines; and interaction with vascular and blood cells; (3) treatment-related factors such as radiotherapy^[@CR20]^, chemotherapy^[@CR21]^, surgery^[@CR22]^, and central venous catheterization^[@CR23]^; and (4) complications^[@CR24]^ such as infection, heart failure, renal disease, and pulmonary disease. Therefore, to the risk of PE should be considered in older patients with a malignancy.

Most older patients with lung cancer complicated with PE have no specific presentation. In a previous study enrolled 24 patients with lung cancer and PE, Chuang *et al*. showed that the most common symptoms were dyspnea (95.8%), hemoptysis (20.8%), cough (20.8%), chest pain (16.7%), body weight loss (8.3%), lower leg edema (8.3%), and shock (8.3%), which are not specific to lung cancer^[@CR25]^. In another study enrolled 28 cases with lung cancer having PE and 56 cases with lung cancer alone, Li *et al*. found that 7.1% of patients with lung cancer complicated with PE were asymptomatic, and the incidence of cough (75.0% *vs*. 66.1%), stethalgia (25.0% *vs*. 7.1%), hemoptysis (14.3% *vs*. 19.6%), syncope (3.6% *vs*. 2.0%), palpitation (28.6% *vs*. 17.9%), and triad syndrome (3.6% *vs*. 0%) were similar between patients having lung cancer complicated with or without PE^[@CR26]^. García Gómez LC conducted a hospital-based, case-control study included 413 patients with PE, 124 of whom were 80 years or older. Compared with the younger patients (\<80 years), the main symptoms presented in elderly patients are dyspnea (73.4% vs 63,7%), chest pain (26.6% vs 39.5%) and cough/hemoptysis (31.3% vs 18.9%) \[11\]. Therefore, older patients with PE are less likely to present with chest pain and more likely to be hypoxic or have syncope^[@CR27],[@CR28]^. In our study, 75.5% of older patients with PE presented with dyspnea, 9.4% with chest pain, and 3.8% with syncope, while 11.3% were asymptomatic. Moreover, typical symptoms of PE may disappear over time, giving rise to missed and delayed diagnosis^[@CR29]^. Therefore, older patients with lung cancer complicated with PE are more likely to have common symptoms of lung cancer.

In the current study, patients with PE had a poorer prognosis. PE is a potentially fatal complication of venous thrombosis in patients with cancer. In 2010, the overall age-adjusted PE mortality rate was 21.0 per 100000. From 2000 to 2010, PE mortality declined in men and women over 55 years^[@CR30]^. Meanwhile, in normotensive patients with PE with no evidence of right ventricular dysfunction, short-term mortality was 2%; while mortality rate rose to 30% in patients with shock and up to 65% in those with cardiac arrest^[@CR31]^. In our study, 8 patients died of PE, including 5 patients in the intermediate-risk, 2 patients in the high-risk subgroups who died at 3 months of follow-up and 1 patient in the intermediate-risk subgroup who died at 6 months of follow-up. In previous studies, PE-related mortality in patients with lung cancer varied between 0.6% and 10%^[@CR26],[@CR32]^, which was comparable with the 8.7% of PE-related mortality PE in our study. In addition, the effect of survival has been shown to be more prominent in patients who develop PE early in the course of cancer^[@CR25]^. A median time to development of PE after lung cancer diagnosis of 3.5 months (1--6.5 months) has previously been reported^[@CR22]^. Majority of patients in the current study (86.8%) developed PE within 3 months after the diagnosis of lung cancer, which might further increase the rate of mortality. In addition, in our study, 69.8% of patients with lung cancer were in stages III and IV when PE was diagnosed, which decreased the survival time further. In the CANTARISK study, high risk of VTE (VTE-RS score ≥3) was associated with a markedly increased risk of early mortality (*HR* = 2.076, 95%*CI*: 1.607--2.681)^[@CR33]^. Furthermore, patients with lung cancer and PE have been shown to have a significantly shorter survival time compared with patients without PE (243.5 d *vs*. 327 d, *P* = 0.01)^[@CR25]^. Similarly, the median survival time of PE patients has been reported to be shorter than that of non-PE patients (6.65 months *vs*. 17.0 months)^[@CR22]^. Furthermore, compared with patients with asymptomatic PE, those with symptomatic PE have been shown to have a markedly shorter median survival time (2.8 months *vs*. 7.2 months)^[@CR34]^. Consistent with previous studies, we found that older patients with lung cancer and PE had significantly shorter median survival time compared with those without PE (4.3 months *vs*. 9.2 months). However, the median tumor-related survival time was similar between the two groups (7.1 months *vs*. 9.7 months, *P* = 0.165). The higher mortality associated with PE indicates the necessity to identify accurate predictors of PE to lower the incidence in high-risk patients with lung cancer^[@CR35]^.

Patients in this study had multiple risk factors for PE. Previous studies have identified that advanced age is a risk factor for PE^[@CR36]^. The results of our study were consistent with previous findings, with advanced age (≥77 years) found to be associated with a 2.58-fold increased risk for PE. However, in a previous study conducted in Japan among 235,104 patients with lung cancer treated with platinum-based chemotherapy, 675 had VTE during hospitalization. Patients older than 70 years were at the lowest risk for VTE (*OR* = 0.59, 95%*CI*: 0.44--0.79), which might be explained by differences in dose and duration of chemotherapy between older and younger patients^[@CR21]^. Several studies have confirmed that patients with PE have a significantly higher D-dimer level, and PE could potentially be ruled out in patients with a negative D-dimer result (\<500 mg/L) and a Well score of 4 or less^[@CR37]^. However, older patients presenting with PE had an increased level of D-dimer, and the age-adjusted D-dimer, which is calculated as the patient age multiplied by 10 mg/L in patients older than 50 years^[@CR38]^, is associated with a 5% absolute increased efficiency compared with a fixed threshold (500 mg/L)^[@CR39],[@CR40]^. Additionally, advanced stage of lung cancer has been shown to be related to higher risk of PE^[@CR41]^. We also found that clinical stage III--IV was an independent risk factor for PE in older patients (OR = 2.21, 95%*CI*: 1.03--4.74). Additionally, several studies have demonstrated that patients with adenocarcinoma of the lung had a significantly higher risk of venous thromboembolic events^[@CR42],[@CR43]^. Consistent with previous studies, we found that the most common histologic type in our patient population was adenocarcinoma (52.8%), which was also an independent risk factor for PE. Furthermore, hypoxemia can increase the risk of VTE events^[@CR43]^. Among patients with lung cancer, PaO~2~ was previously identified as a risk factor for PE (OR = 2.7, 95%CI: 1.31--3.98)^[@CR22]^, which was consistent with our findings. Therefore, advanced age, clinical stage III--IV, adenocarcinoma, high D-dimer level, and low PaO~2~ were identified as independent risk factors for PE in the present analysis.

Treatment of VTE in patients with cancer is challenging. Balancing the risk of bleeding to the thrombosis is complicated by a variety of factors. In the landmark CLOT trial including 672 patients with cancer and acute symptomatic VTE, Lee *et al*. found that dalteparin was associated with significantly decreased rate of recurrent VTE and similar risk of major bleeding compared with oral-anticoagulant^[@CR44]^. American College of Chest Physicians Evidence-Based Clinical Practice (ACCP) and European Society of Medical Oncology (ESMO) guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant in VTE prevention and treatment for patients with cancer^[@CR45],[@CR46]^. The direct oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, edoxaban, apixaban have been approved for VTE treatment in the general population^[@CR47]--[@CR49]^. Recently, several studies demonstrated that NOACs were an alternative anticoagulant for the prevention and treatment of VTE in patients with cancer. The RECOVER and RECOVER II trials showed that the rate of recurrent VTE or VTE-related mortality was not significant different between dabigatran and warfarin groups in patients with cancer (3.5% vs 4.7%)^[@CR47]^. The EINSTEIN-DVT and EINSTEIN-PE trials demonstrated also showed similar VTE recurrence among patients treated with rivaroxaban and those treated with a LMWH and Vitamin-K antagonist^[@CR50]^. In the AMPLIFY trial, recurrent VTE was comparable among patients with cancer treated with apixaban and those treated with enoxaparin/warfarin (3.7% vs 6.4%)^[@CR48]^. In the HOKUSAI-VTE trial, oral edoxaban was associated with similar rate of VTE recurrence and major bleeding compared with dalteparin in patients with cancer-associated VTE^[@CR51]^. Therefore, the clinical effect of NOACs for VTE prevention and treatment is still uncertain. Many ongoing trials such as CAP trial, CARAVAGGIO trial, CASTA-DIVA trial, CANVAS trial is evaluating the safety and efficacy of NOACs in cancer patients.

Limitations {#Sec15}
-----------

This study has several limitations. First, the use of PSM method for patient selection is a potential weakness. There might be remaining imbalances in terms of confounding^[@CR52]^. Second, ours was a relatively small cohort study, meaning that the primary analysis may have been underpowered and these finding require further confirmation. Third, this was a single-center study. Therefore, selection bias might have occurred during identification of the patients, and our data cannot be directly extrapolated to other health centers. Fourth, the REVERSE study showed that the residual PE after 5--7 months of oral anticoagulant therapy was a predictor for recurrence^[@CR53]^. However, we did not evaluate the effect of residual PE after the anticoagulant and/or thrombolysis therapy on the primary and secondary outcomes. Fifthly, the study analyzed the characteristics of cancer associated PE in the past 10 years, and we cannot exclude that accuracy of CTPA, venous ultrasound and anticoagulant and anti-tumor treatment options used in our study may influence our results. Finally, most patients were treated with LMWH or warfarin, we cannot comment on whether NOACs would affect the results^[@CR54]^. Therefore, due to the limitations of this study discussed above, further studies are required to verify the present findings.

Conclusion {#Sec16}
==========

In conclusion, older patients with lung cancer complicated with PE have atypical clinical manifestations and high mortality. Advanced age, clinical stage III--IV, adenocarcinoma, high serum D-dimer, and low PaO~2~ are independent risk factors for PE. Early prevention and treatment of PE in high-risk populations is needed to improve the prognosis of these patients.
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